Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma

This article was originally published here

Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz.  Jazz will be responsible for further development, regulatory activities and commercialisation. Under

The post Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply